Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Future oncology"
DOI: 10.1080/14796694.2025.2495542
Abstract: Advanced esophageal squamous cell carcinoma (ESCC) patients had poor prognosis and few effective drugs based on the randomized controlled trials (RCTs). In such a circumstance, recent RCTs have shown the clinical efficacy of immune checkpoint… read more here.
Keywords: escc patients; cell; treatment advanced; advanced escc ... See more keywords
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-22-1169
Abstract: Background Esophageal cancer (EC) is the seventh most common cancer in the world, with 604,000 new cases diagnosed each year. Immune checkpoint inhibitors (ICIs) including programmed death ligand-1 (PD-L1) inhibitors have demonstrated a considerable survival… read more here.
Keywords: advanced escc; treatment advanced; line treatment; second line ... See more keywords